A. Lavolé
Sorbonne Université · 226 works · 3,658 citations · h-index 31
Top works
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
- Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia
- Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial
- Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab
- Neutrophils Promote Aerogenous Spread of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features
- Six-month prognosis of patients with lung cancer admitted to the intensive care unit
- 1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)
- Risk of AIDS‐defining cancers in HIV‐1‐infected patients (1992–2009): results from FHDH‐ANRS CO4
- Skin Toxicities Compromise Prolonged Pemetrexed Treatment
- Risk of AIDS-Defining Cancers Among HIV-1–Infected Patients in France Between 1992 and 2009: Results From the FHDH-ANRS CO4 Cohort
- LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
- Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung
- Lung cancer in HIV infected patients: facts, questions and challenges
- Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review
- Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
- Lung cancer, a new challenge in the HIV-infected population
- Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).
- Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial
- Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
- Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer